Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

n the United States there are approximately 1,500 new cases each year.

About Ibrutinib
Ibrutinib is an investigational drug designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating apoptosis, adhesion, and cell migration and homing. Through these multiple actions, BTK helps to direct malignant B-cells to lymphoid tissues, thus allowing access to a micro environment necessary for survival.

The effectiveness and safety of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma. To date five Phase III trials have been initiated with ibrutinib and a total of 27 trials are currently registered on clinicaltrials.gov.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization.
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... and STAMFORD, Conn. , Aug. 31, ... Eisai Co., Ltd., and Purdue Pharma L.P. announced today ... for the development and commercialization of Eisai,s clinical candidate ... entering Phase III clinical development for the treatment of ... agreement, Eisai and Purdue Pharma will share the costs ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ... the "Prescription Pain Drugs - Including Opioid, ... Global Markets, Competitors and Opportunities: 2015 - 2020 ... Pain is defined as an ... or potential tissue damage. At some point, everyone ...
(Date:8/28/2015)... Fla. , Aug. 28, 2015  With the ... reaching deadlier heights, Jacksonville -based ... Philip Hemphill is helping to explain why fentanyl ... is approximately 40 to 50 times more potent than ... recreational users as heroin, the risk of death skyrockets. ...
Breaking Medicine Technology:Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
(Date:8/31/2015)... Pittsburgh, PA (PRWEB) , ... August 31, 2015 ... ... television than their peers may be at a greater risk for injury, potentially ... risk-taking behaviors, a University of Pittsburgh Graduate School of Public Health analysis discovered. ...
(Date:8/31/2015)... ... August 31, 2015 , ... Kognito , a ... their competencies in managing challenging conversations, announced today that Glenn Albright, Ph.D., the ... of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) Summit taking ...
(Date:8/31/2015)... ... August 31, 2015 , ... On Saturday, May 30th, 2015, Best ... Adams County Fairgrounds in Mendon, IL. The purpose behind this concert was to raise ... neighboring town, Quincy. Best Drug Rehabilitation’s sponsorship of “Music with a Mission” helped with ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... e-Spirit to future-proof its content management system (CMS) and make website updates quicker ... Sports in making the websites of the Bundesliga (the German equivalent of the ...
(Date:8/31/2015)... ... 2015 , ... “My mother and husband use oxygen therapy and the tubing ... there could be a comfortable way to prevent the irritation, so I invented this.” ... a more secure way to anchor the cannula tubing used in oxygen therapy and ...
Breaking Medicine News(10 mins):Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3Health News:Kognito’s Glenn Albright to Present at DCoE Summit 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:On the Ball with FirstSpirit: German Soccer League (DFL Digital Sports) Opts for e-Spirit’s CMS 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2
... Babies born to HIV-positive mothers and given the antiretroviral ... to prevent infection via breast-feeding are at high risk ... a team of researchers report. But the investigators highlight ... mother-to-child HIV transmission in breast-fed infants. , ...
... Corporation (NYSE: CBM ) is pleased ... Chief Executive Officer, will be presenting at the ... 9:00 a.m. PST at the Westin St. Francis, ... http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )A live webcast of the presentation ...
... Jan. 5 Volcano Corporation,(Nasdaq: VOLC ), ... for the diagnosis and treatment of coronary and peripheral ... January 6, to,discuss its acquisition of Axsun Technologies, Inc., ... The teleconference call and webcast will begin ...
... Few things are as tiresome as house hunting and ... down pat. Tripping nimbly from one abode to another, ... than the original tumor. Although little has been known ... down roots, researchers at the Stanford University School of ...
... the U.S. each year have been exposed to alcohol or illicit ... the National Center on Substance Abuse and Child Welfare. If removed ... in foster care longer, and chances are very low that they ... led by Joseph P. Ryan, a faculty member in the School ...
... with Operation Smile to See the Difference, Make a ... through March 2009, Crest and Oral-B are encouraging people across the ... while also making a difference in children,s smiles worldwide. When ... difference in their smile. People can also make a ...
Cached Medicine News:Health News:Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV 2Health News:Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV 3Health News:Reminder: Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction 2Health News:'Relocation' plan of metastatic cancer cells uncovered by Stanford researchers 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 2Health News:'Recovery coaches' effective in reducing number of babies exposed to drugs 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 2Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 3Health News:Crest and Oral-B Challenge America to See The Difference in Their Smile and Make A Difference in Children's Smiles Around the World 4
Low Profile Design for Precise Anchor Placement...
... utilizes a suprapubic approach to treat ... urethral hypermobility and/or intrinsic sphincter deficiency ... needles and a self-fixating sling with ... for intra-operative tension refinement without mesh ...
... The Uretex® Trans-Obturator ... excellent tension-free, self-anchoring support ... The polypropylene mesh maintains ... flat placement under the ...
... Delivers the durability of natural ... benefits of ingrowth and natural ... or exceeds all applicable state ... Allograft Tissue also reduces OR ...
Medicine Products: